Anika Therapeutics Inc (ANIK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $179.50M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anika Therapeutics Inc (ANIK) P/E Ratio & Valuation History
Anika Therapeutics (ANIK) trades at 18.7x trailing earnings and 1.4x sales. Its P/S of 1.4x is below its 5-year median of 2.3x. Its forward P/E is 13.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 39.6% higher over the next year. Its free cash flow yield is 1.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 18.7x |
| Forward P/E | 13.4x |
| Price to sales | 1.4x |
| Price to book | 1.3x |
| EV/EBITDA | 41.7x |
| Price to FCF | 75.4x |
| EV/FCF | 55.8x |
| PEG | 1.3 |
| FCF yield | 1.3% |
Historical Medians
Against its 10-year medians, its P/S is 64.1% below 3.9x and its P/B is 27.8% below 1.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.4x | 2.3x | 3.9x |
| P/B | 1.3x | 1.5x | 1.8x |
Valuation History
Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 22.8x in 2016 to 63.7x in 2020. 2020 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $9.61 | N/A | 1.2x | 1.0x |
| 2024 | $16.46 | N/A | 2.0x | 1.6x |
| 2023 | $22.66 | N/A | 2.8x | 1.6x |
| 2022 | $29.60 | N/A | 3.8x | 1.5x |
| 2021 | $35.83 | N/A | 3.5x | 1.8x |
| 2020 | $45.26 | 63.7x | 4.9x | 2.4x |
| 2019 | $51.85 | 25.3x | 6.4x | 2.6x |
| 2018 | $33.61 | 26.1x | 4.6x | 1.8x |
| 2017 | $53.91 | 27.4x | 7.0x | 3.1x |
| 2016 | $48.96 | 22.8x | 7.0x | 3.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ANIK
What is ANIK's forward P/E ratio?
Anika Therapeutics has a forward P/E ratio of 13.4x.
Is ANIK stock overvalued?
GNG's valuation label for ANIK is Undervalued.
What is ANIK's price to sales ratio?
Anika Therapeutics has a price to sales ratio of 1.4x.
What is ANIK's PEG ratio?
Anika Therapeutics has a PEG ratio of 1.3.
ANIK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors